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0959-8049/ª 2019 Elsevier Ltd. All righAbstract Aim: The aim of the study is to analyse radiotherapy quality assurance (RTQA)
processes in the treatment of paediatric central nervous system (CNS) tumours across Europe.
Methods: The RTQA aspects of major past and current European trials for paediatric CNS
tumours were reviewed based on study protocols and publications. A survey among radiation
oncologists and paediatric oncologists about the practices of RTQA in paediatric CNS tu-
mours across European countries was also performed.
Results: Several (inter)national initiatives to implement RTQA are being developed across
Europe, with an apparent paradigm shift from retrospective to prospective RTQA. Experts
from 21 of 29 contacted countries responded to the survey. National consensus guidelines
for paediatric CNS tumours are available in 10 of 21 countries. Twenty-one of 33 expertsartment, EORTC Headquarters, Av. E. Mounier 83/11, 1200, Brussels, Belgium.
.org (T. de Rojas).
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T. de Rojas et al. / European Journal of Cancer 114 (2019) 36e46 37believe that the level of involvement of paediatric radiation oncologists in the meetings and
activities of the national paediatric oncology societies is adequate. Central storage of radio-
therapy data is available in France, Germany and Denmark. RTQA programmes for paediat-
ric brain tumours are available in 7 countries. Twelve of 21 experts believe that there is a well-
established national referral network for the radiation treatment of paediatric patients in their
respective countries.
Conclusion: As a result of the review and survey, the following measures are proposed: (1)
developing international RT guidelines for paediatric CNS tumours, (2) improving the collab-
oration between paediatric oncologists and paediatric radiation oncologists, (3) building a cen-
tral storage system for RT data, (4) implementing international prospective RTQA
platforms and (5) promoting European referral networks to reduce inequality.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
The improved survival rates of paediatric patients with
central nervous system (CNS) tumours over recent de-
cades are accompanied by a growing concern about
long-term sequelae and the quality of life of the survi-
vors [1]. Radiotherapy (RT) continues to be a corner-
stone in the curative treatment of paediatric brain
tumours, next to surgery and to a somewhat lesser
extent chemotherapy. However, the potential severe
long-term sequelae of CNS irradiation are well known
[2]. Improved diagnostic imaging and more advanced
RT techniques and equipment, for example, intensity-
modulated RT and particle therapy, are tackling this
issue, at the price of growing complexity and the need
for highly specialised centres [3,4]. Through increasingly
conformal RT, the dose is better targeted to the tumour,
minimising the dose to normal brain structures outside
the planning target volume and hence reducing the risk
of long-term side-effects [5].
A clear description of the RT procedures, including
equipment, patient positioning and simulation, volume
selection and definitions, doseevolume constraints,
treatment planning and verification, is needed to achieve
treatment compliance and uniformity between in-
stitutions. In this complex technical setting, quality
assurance (QA) programmes are essential because data
demonstrate that deviations in RT can result in
increased morbidity and mortality [6,7].
The implementation of radiotherapy quality assur-
ance (RTQA) systems is, however, far from universally
achieved. Defining accurately the current practices of
radiation oncologists and the existing RT resources at a
supranational level is a major challenge. Lievens et al.
recently drew an accurate picture in adult oncology, but
not without difficulty and only in the frame of a long-
term cooperative project (Health Economics in Radia-
tion Oncology [HERO]) [8,9]. A similar paediatric-
specific project is currently being carried out by
Demoor-Goldschmidt et al. [10], with the first resultshighlighting the difficulties in obtaining accurate and
complete data.
To analyse RTQA processes in the treatment of
paediatric CNS tumours in Europe, we reviewed the
RTQA aspects of past and current European collabo-
rative trials, and we performed an international survey
of radiation and paediatric oncologists on RTQA
practices in Europe.
2. Past and present
2.1. Status of RTQA in paediatric CNS tumours in
Europe
2.1.1. Materials and methods
A literature review to assess and summarise the current
situation of RTQA in paediatric brain tumours across
Europe was performed. In addition, RTQA aspects of
relevant trials in the available study protocols and
publications were reviewed, and the European Organi-
sation for Research and Treatment of Cancer (EORTC)
RTQA levels were assessed [11]. Since 2006, RTQA re-
quirements for sites participating in EORTC trials have
been classified into five different levels. General cre-
dentialing (level 1) helps to ensure delivery of RT of
minimum acceptable quality across all sites and consists
of a facility questionnaire and external reference
dosimetry audit. Protocol-specific institutional tests
(levels 2e5) help verify that external beam RT planning
and delivery is congruent with the study guidelines: level
2 includes dummy runs; level 3, limited individual case
review; level 4, extensive individual case review and level
5, complex dosimetry checks.
2.1.2. Results
A paradigm shift from retrospective to prospective
RTQA is observed over recent years. Although in older
studies, if any QA was performed at all, retrospective
assessments were the norm [7,12,13], the more recent
trials for paediatric brain tumours predominantly
Table 1
RTQA aspects in recent clinical trial protocols for paediatric CNS tumours.
Clinical trial Study start Study end Tumour type RTQA Level of control Retrospective vs
prospective
EORTC
RTQA level
Required compliance Publication of
RTQA aspects
Conclusion(s) of
RTQA
publication
Completed trials
HIT-SIOP PNET-3
[12,14]
March
1992
January 2000 MB (M0-M1) Yes International Retrospective Level 3 UNK Separately from
the primary
publication (1
year later)
RT duration
(<50 days)
impacts EFS
HIT-SIOP PNET-4
[15,16]
January
2001
December
2006
MB (SR) Yes National Prospective for some
national groups;
retrospective (within
1 year) for all
patients
Level 4 Mandatory for CSI;
Optional for
posterior fossa/
tumour bed
QA exercise
(dummy run)
before study
opening (in some
countries)
Ambiguities in
draft protocol,
areas of
interclinician
variability.
Protocol revised
and improved.
HART Milan [17] 1998 2007 MB (MTX) Yes Local (only
one institution
administering
RT)
Retrospective UNK (not
specified)
NA Within primary
publication (not
detailed)
‘RT at the same
institution
following the
local technical
guidelines and
quality control
process’
French M-SFOP 98
[18]
December
1998
October 2001 MB (SR) Yes National Prospective for CSI,
retrospective for
tumour bed boost
Level 4 Mandatory Within primary
publication
(somewhat
detailed) and
following
preexisting
national
guidelines
Prospective RT
review is feasible
and useful (no
isolated frontal
relapse occurred
compared with
seven in the
previous report)
SFOP HR [19] January 1993 June 1999 MB (HR) Yes National Retrospective Level 4 Mandatory Within primary
publication
(somewhat
detailed) and
following
preexisting
national
guidelines
EFS not
statistically
different for
patients with no
or one major
deviation or for
patients with
more than one
LGG 2004 [20] April 2004 April 2012 LGG Noa National Retrospective None Mandatory (not
clearly specified)
No mention in
primary
publication
NA
SIOP CNS GCT II
(NCT01424839)
October 2011 June 2018 IGCT Noa National Retrospective None Mandatory (not
clearly specified)
NA NA
Ongoing trials
HIT-SIOP PNET-5
(NCT02066220)
June 2014 Open MB (SR) Yes National þ
international
Prospective Level 4 Mandatory for CSI,
boost and any
NA NA
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T. de Rojas et al. / European Journal of Cancer 114 (2019) 36e46 39include prospective RTQA programmes (Table 1). An
example of this paradigm shift is given by the HIT-SIOP
PNET trials. In PNET-3, the RTQA review (EORTC
RTQA level 3) was performed retrospectively and pub-
lished one year after the trial’s primary publication
[12,14]. In PNET-4, however, RTQA was performed
prospectively by some national groups and retrospec-
tively within one year for all patients [15]. RTQA was
considered mandatory to participate in the trial for
craniospinal irradiation (CSI; EORTC RTQA level 4).
Furthermore, a QA exercise (dummy run, level 2) was
performed in the United Kingdom (UK) centres before
the opening of PNET-4, in which ambiguities in the
draft protocol and areas of interclinician variability in
target volume delineation were found. Consequently,
the protocol was revised and improved before the
opening of the trial [16]. In the ongoing PNET-5 trial
(NCT02066220), an amendment has been submitted to
have RTQA performed prospectively and mandatory
for both CSI and the boost.
These examples of RTQA, although effective in the
clinical trial setting, leave patients treated outside that
context (‘real-world’ patients) behind. There is guidance in
some countries which recommends that RT target volume
and organ at risk delineation should not be left to one
individual but should be peer-reviewed by an experienced
colleague before planning and treatment [21]. There is also
specific paediatric guidance in this regard [22].
Problems may arise when single-centre treatment
protocols or clinical trials carried out in few highly spe-
cialised centres are transferred towider real-world settings
[23]. One example of this was the generalisation of the
hyperfractionated accelerated RT (HART)eintensive
chemotherapy strategy [17] for metastatic medulloblas-
toma from a single institution in Milan to a wider inter-
national setting. The results (3-year overall survival [OS]
of 56% [24]) were far below those of the original publi-
cation (3-year OS of 77%). One of the reasons given by the
authors for not being able to replicate the original trial
results was the differences in treatment delivery, which
RTQA measures could have helped to reduce. Further-
more, severe cases of neurotoxicity, which were not re-
ported in the original publication, were found in the UK
cohort for complex, multifactorial reasons [25]. The re-
ported cases of myelitis and other grade 3e4 CNS toxic-
ities seemed to associate with the overlapping of the upper
cervical spine within posterior fossa boost volumes in
conjunction with neurotoxicity associated with thiotepa.
As a result of these real-world studies, the HART-
intensive chemotherapy strategy was abandoned in the
UK and internationally [24,25].
More recently, a European platform for RTQA in
paediatric oncology, named QUARTET (QUAlity and
excellence in RadioTherapy and imaging for children and
adolescents with cancer across Europe in clinical Trials),
has been developed [26]. QUARTET will support the
implementation of RTQA programmes in several trials
T. de Rojas et al. / European Journal of Cancer 114 (2019) 36e4640(e.g. SIOP PNET-5, SIOP-EP-II). Although currently it
only includes patients participating in clinical trials, one
of the aims of QUARTET is to eventually expand to
patients treated outside trials as well [27].
2.2. Survey on practices across Europe of paediatric
oncologists and radiation oncologists involved in the
treatment of brain tumours
2.2.1. Materials and methods
One reference paediatric radiation oncologist and/or
one reference paediatric oncologist of 29 countries (27
European countries plus Israel and Turkey) involved in
the treatment of CNS tumours were contacted in
February 2018 by email and invited to complete an
online 12-item questionnaire (Supplementary Material
1). Possible participants were found through
networking/suggestion by international leaders in the
field.
The answers provided as ‘free text’ were used to
reconcile conflicting responses between experts from the
same country. If not possible, a distinction was made
depending on the best suited expertise for each question:
the reply of the radiation oncologists was given prefer-
ence for questions 3, 4, 5, 8 and 9; the reply of the
paediatric oncologists was given preference for ques-
tions 1, 2, 7 and 10 and questions 6, 11 and 12 did not
require this distinction.
To compare the number of RT centres between
countries, the total number was divided by theFig. 1. Participation acpopulation of each country. Population data were ob-
tained from the Central Bureau of Statistics for Israel
and from Eurostat for the other countries [28,29].2.2.2. Results
Forty-eight experts (20 radiation oncologists and 28
paediatric oncologists) from 29 countries were con-
tacted; 33 experts responded: 18 of 20 (90%) radiation
oncologists and 15 of 28 (54%) paediatric oncologists
from 21 countries participated in the survey (Fig. 1). The
outcome of the survey generated the following answers:
(Q1) The median number of centres per country treating
paediatric patients with cancer is 6.2 (range 0.6e11.9)
per 10 million inhabitants.
(Q2) The median number of centres treating paediatric pa-
tients with CNS tumours is 4.8 (range 0.6e11.9) per 10
million inhabitants.
(Q3) The number of RT departments that treat paediatric
patients with CNS tumours varies across countries, with
a median of 3.7 (range 0.6e10.7) per 10 million in-
habitants (Fig. 2).
(Q4) There is a well-established referral network for the RT
treatment of paediatric patients in 12 of 21 (57%)
countries (Fig. 3).
(Q5) Four of 21 countries (France, Germany, the
Netherlands, the UK) have a national paediatric RT
society.
(Q6) Involvement of radiation oncologists in meetings of the
respective national paediatric oncology societies is
considered ‘(somewhat) sufficient’ by 64% (21/33) ofcording to country.
Fig. 2. Radiotherapy centres treating paediatric CNS tumours per country population (number per 10 million inhabitants). (Survey
question #3). RT, radiotherapy.
Fig. 3. Existence of a well-established national referral network for the radiotherapy treatment of paediatric patients: Map showing re-
sponses by country. (Survey question #4). Of note: In case of disagreement, the opinion of the radiation oncologist is highlighted in the
map. No respondents ‘strongly disagreed’ with the statement.
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33) (Fig. 4). The proportion of participants considering
the involvement ‘insufficient’ is higher among radiation
oncologists (33%; 6/18) than among paediatric oncolo-
gists (7%; 1/15).
(Q7) National consensus guidelines for the treatment of
paediatric CNS tumours exist in 48% (10/21) of the
countries.
(Q8) National RTQA programmes for the treatment of
paediatric CNS tumours are in place in 33% (7/21) of
the participating European countries. These pro-
grammes are very heterogeneous, ranging from peer
review of selected cases to well-established, compre-
hensive systems.
(Q9) Three countries (14%; 3/21) have a central storage sys-
tem for RT data in place. In all of them (Denmark,
France and Germany), the complete digital imaging and
communications in medicine (DICOM)-RT plans are
collected as part of the data.
(Q10) In all participating countries, paediatric patients with
CNS tumours have access to a particle therapy facility,
either nationally or abroad, and are supported by the
public health system. In 8 of 21 countries, proton fa-
cilities are available within their own borders [30].
(Q11) Most participants (85%; 28/33) (strongly) agreed that all
paediatric patients with CNS tumours are granted equal
access to quality RT in their respective countries. Five re-
spondents showed concerns that this might not be the case
all over their country (Israel, Italy, Spain, Switzerland,
Turkey) because of differences in geographical distribution
and in the level of experience among RT centres.
(Q12) Nearly all (91%; 30/33) consulted experts believe that
the patients would benefit to a considerable or to a great
degree from a European RTQA guideline for paediatric
brain tumours.
The full tabulated breakdowns of responses can be
found in Supplementary Material 2.3. Discussion: Future
The review and survey we have performed helped to
identify the following areas of improvement.0% 10% 20% 30% 40%
Ped. Oncologists
Rad. Oncologists
Involvement of radia
Insuﬃcient Somewhat insuﬃcient Neither insuﬃci
Fig. 4. Opinion about the level of involvement of paediatric radiation o
oncology societies. (Survey question #6).3.1. Standardisation of treatment: guidelines
Clinical guidelines are an affordable and straightfor-
ward approach towards standardisation of treatments,
especially for the management of rare diseases, such as
paediatric malignancies. This is particularly important
for patients treated outside clinical trials or for whom no
clinical trials exist [31]. However, through our survey,
we found out that only 48% of the participating coun-
tries have national consensus guidelines for the treat-
ment of paediatric CNS tumours.
National and/or international guidelines can be a first
step to unify strategies, facilitate QA and improve the
management of children with CNS tumours. Participa-
tion in clinical trials remains a paramount treatment
strategy in paediatric oncology, but still, guidelines are
often needed for aspects not covered in clinical trials or
time periods where these are not open.
Moreover, almost all (91%) consulted experts believe
that the patients would benefit from a European RTQA
guideline for paediatric brain tumours. There seems to
be an increasing awareness of the necessity for a com-
mon effort across European CNS tumour specialists to
ensure high-quality RT treatment. In that line, the Eu-
ropean society of paediatric oncology (SIOPE) Brain
Tumour Group has recently published a consensus
guideline on craniospinal target volume delineation for
high-precision RT, which has the potential to improve
the consistency of craniospinal delineation [32].
Looking at similar experiences in adult oncology,
several international, disease-specific RT guidelines exist
for adult cancers, based on published level 1 or 2 evi-
dence and/or expert consensus, detailing delineation and
dose recommendations (e.g. for glioblastoma [33,34]).
While level 1 or 2 evidence is not always available,
especially in a paediatric and rare disease context,
consensus is presumably reachable by the international
neuro-oncology community. In parallel, regular audit
procedures should be implemented at a local, national
and international level to ensure the centres comply with
the directives of the guidelines. This could raise the50% 60% 70% 80% 90% 100%
on oncologists
ent nor suﬃcient Somewhat suﬃcient Suﬃcient
ncologists in the meetings and activities of their national paediatric
T. de Rojas et al. / European Journal of Cancer 114 (2019) 36e46 43standards for RT treatment beyond clinical trial proto-
col provisions.
3.2. Multidisciplinary work: collaboration between
paediatric specialists and professional organisations
The importance of multidisciplinary tumour boards for
paediatric tumours has already been reported [35].
Beyond this, close collaboration between paediatric
oncologists, neurosurgeons and radiation oncologists is
critical for providing quality care and for enabling the
development of new RTQA initiatives. However, about
one-third (30%) of the consulted experts believe that the
level of involvement of paediatric radiation oncologists
in the meetings and activities of the national paediatric
oncology societies is inadequate. In fact, the discontent
seems higher among radiation oncologists, with 33% of
them considering said involvement to be insufficient.
These numbers leave room for improvement.
Only one-fifth (19%) of the participating countries
have a national paediatric RT group. There is a need to
involve all the paediatric radiation oncology groups or
societies to share experiences and recommendations at a
supranational level. This is particularly relevant in
smaller countries, where the number of specialists is low,
and it may not be practical or useful to have a national
group. Recently, the SIOPE Radiotherapy Working
Group has been created, which will benefit all national
organisations.
One of the aspects that this new group could tackle is
the training and certification of paediatric radiation
oncologists. In the same line of pushing childhood CNS
cancer care towards excellence, this remains an area of
concern that could benefit from international agreement
[22,36].
Although this goes beyond the European scope of
this work, it is important to recognise the advanced
status of QA practices in North America, with vast
experience in central reviews, educational sessions,
benchmarking of complex techniques and dummy runs,
online planning atlases and so on [37e39]. Despite the
differences with the European health system landscape,
we ought to benefit from the North American experience
and lessons learnt.
3.3. Central storage of RT data
An important step towards the implementation of
RTQA systems is central storage of RT data, done in 3
of 21 European countries according to our survey (in the
meantime, a fourth countrydBelgiumdhas started
central storage as well). An optimal storage should
include the full planning and the final report, with the
complete DICOM-RT plan and any auxiliary imaging
used to define the target(s); all treatment deviations
should be documented and stored as well. An affordable
first approach for this storage could be the use ofnational cancer registries, which is already being done
by some countries (e.g. Belgium and the Netherlands). A
shared database has the additional advantage of facili-
tating the link with other clinical and translational data
(long-term follow-up, biobanking, pathology reports,
tumour genomics and so on) while maintaining
compliance with local data protection regulations, such
as the new General Data Protection Regulation in
Europe [40].
International storage has additional advantages. Pan-
European platforms allow including all types of paedi-
atric patients with brain tumours, regardless of their
inclusion in clinical trials, as seen with the SIOPE-
diffuse intrinsic pontine glioma (DIPG) registry [41].
This would help to amplify our knowledge with real-
world data and eventually reduce the gap between the
outcome of patients enrolled within and outside clinical
trials.
3.4. RTQA programmes
According to our survey, only 7 of 21 European coun-
tries have RTQA programmes in place for the treatment
of paediatric brain tumours. In addition, the existing
programmes are heterogeneous with respect to the levels
of RTQA [11], or in some cases, part of international
trials with mandatory RTQA.
In our opinion, the ultimate aim is to have a pro-
spective RTQA system in which each new RT plan is
reviewed by an international expert panel before the
treatment is applied, which is challenging in clinical
practice because of time constraints and financial diffi-
culties. This is especially the case in children with brain
tumours in which the clinical situation may not allow
delays in the start of the treatment or for tumours in
which a late onset of RT reduces survival [42]. Pro-
spective review is being currently implemented in some
trials (e.g. SIOP PNET-5). Until QUARTET can be
extended across all types of CNS tumours and to pa-
tients treated outside clinical trials [27], the standards
and practices could be improved by a systematic
continuous retrospective review.
3.5. Equal access to RT for paediatric patients with CNS
tumours across Europe
At a national level, no differences were reported in the
access to RT treatment in our survey for most (85%) of
the participating countries. At a European level,
inequality prevails according to previous studies, with a
well-known inequality of outcomes for paediatric pa-
tients with cancer [43,44]. One of the reasons could be
the imbalance in RT resources, with a wide range of
levels of access to best-care facilities and specialists
across countries [10]. In fact, according to our survey,
there is wide variability in the number of RT centres that
treat paediatric patients with CNS tumours, with some
T. de Rojas et al. / European Journal of Cancer 114 (2019) 36e4644countries having 20 times more centres per million in-
habitants than others. These numbers are reflecting the
differences in national healthcare policies and/or the
socio-economic status. However, more important than
the number of centres per million inhabitants is the
number of patients treated per centre, given the growing
complexity of paediatric RT. Although the minimum or
optimal number of patients per centre is not established,
centres treating a higher number of paediatric cancers
will benefit from their experience in providing best care.
The factors leading to inequality across European
countries extend beyond the distribution of resources,
with insufficient networking being an important part of
the equation. According to the survey, only 57% of the
experts believe that there is a well-established national
referral network for radiation treatment in their
respective countries. Existing national and European
referral networks for RT for paediatric brain tumours
should be expanded and new ones created. The recently
launched European Reference Network for Paediatric
Oncology (ERN PaedCan) [45] could be an appropriate
framework to start implementing referral pathways for
RT in paediatric brain tumours and promoting RTQA
initiatives.
The weaknesses of our study need to be acknowl-
edged. The review of RTQA aspects in past and current
European trials is not exhaustive; however, our purpose
was to highlight some relevant examples to expose the
ongoing paradigm shift towards prospective RTQA. In
addition, not all European countries responded to the
international survey. Nonetheless, the inclusion of 21
participating countries from all European regions allows
the drawing of a reasonably comprehensive European
perspective. The limited number of participating experts
responds to the purpose of selectively involving highly
specialised, reference paediatric oncologists and radia-
tion oncologists treating CNS tumours.
In conclusion, an ongoing audit of our medical
practice is desirable in all aspects of paediatric oncology,
but QA has become increasingly important in RT for
CNS tumours as this aspect of treatment becomes ever
more technical and complex. Childhood cancers are rare
compared with adult tumours, with children accounting
for only about 1% of all RT patients. Within this small
number, there is an increasing diversity of diseases and
subgroups requiring individualised treatment. This
means that even experienced clinicians in large centres
see only a limited number of any one type of treatment.
RTQA allows expertise to be spread from more expe-
rienced to less experienced centres, for the benefit of
patients, for example, through real-time review of con-
tours and dosimetry. Several positive initiatives, both
national and international, are being undertaken to
implement RTQA in the treatment of paediatric patients
across Europe, and there is still room for improvement.
Creating a European RTQA guideline for paediatric
CNS tumours, improving collaboration betweenpaediatric radiation oncologists and other specialists,
building a European central storage system for RT data,
implementing international RTQA platforms and pro-
moting European referral networks to reduce inequality
are measures that will hopefully contribute to improve
the still dismal overall outcome of paediatric patients
with CNS tumours and reduce long-term toxicities.
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